Back to Search Start Over

Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease.

Authors :
Mire CE
Geisbert JB
Agans KN
Versteeg KM
Deer DJ
Satterfield BA
Fenton KA
Geisbert TW
Source :
Emerging infectious diseases [Emerg Infect Dis] 2019 Jun; Vol. 25 (6), pp. 1144-1152.
Publication Year :
2019

Abstract

Nipah virus (NiV) is a zoonotic pathogen that causes high case-fatality rates (CFRs) in humans. Two NiV strains have caused outbreaks: the Malaysia strain (NiV <subscript>M</subscript> ), discovered in 1998-1999 in Malaysia and Singapore (≈40% CFR); and the Bangladesh strain (NiV <subscript>B</subscript> ), discovered in Bangladesh and India in 2001 (≈80% CFR). Recently, NiV <subscript>B</subscript> in African green monkeys resulted in a more severe and lethal disease than NiV <subscript>M</subscript> . No NiV vaccines or treatments are licensed for human use. We assessed replication-restricted single-injection recombinant vesicular stomatitis vaccine NiV vaccine vectors expressing the NiV glycoproteins against NiV <subscript>B</subscript> challenge in African green monkeys. All vaccinated animals survived to the study endpoint without signs of NiV disease; all showed development of NiV F Ig, NiV G IgG, or both, as well as neutralizing antibody titers. These data show protective efficacy against a stringent and relevant NiV <subscript>B</subscript> model of human infection.

Details

Language :
English
ISSN :
1080-6059
Volume :
25
Issue :
6
Database :
MEDLINE
Journal :
Emerging infectious diseases
Publication Type :
Academic Journal
Accession number :
31107231
Full Text :
https://doi.org/10.3201/eid2506.181620